18 November 2015 - NICE has published interim guidance barring patients with advanced bowel cancer from routine NHS access to Merck Serono’s Erbitux and Amgen’s Vectibix, the only two personalised options still available for the disease.

For more details, go to: http://www.pharmatimes.com/Article/15-11-18/NICE_says_no_to_personalised_bowel_cancer_drugs.aspx